Schuster Julius, Cycelskij Igor, Lopresti Adrian, Hahn Andreas
Institute of Food and One Health, Leibniz University Hannover, Hanover, Lower Saxony, Germany.
College of Science, Health, Engineering and Education, Murdoch University, Perth, Australia.
Nat Sci Sleep. 2025 Aug 30;17:2027-2040. doi: 10.2147/NSS.S524348. eCollection 2025.
To assess the effects of magnesium bisglycinate supplementation on insomnia symptoms in healthy adults reporting poor sleep quality.
This randomized, double-blind, placebo-controlled trial enrolled 155 adults aged 18-65 years with self-reported poor sleep quality. Participants were randomly assigned to either magnesium bisglycinate supplementation (250 mg elemental magnesium, daily) or placebo capsules. Sleep quality was assessed using the Insomnia Severity Index (ISI) and additional psychological questionnaires at baseline and multiple time points throughout the study. Generalized linear mixed models (GLMM) adjusted for baseline ISI scores, age, sex, body mass index, and occupation were applied.
The magnesium bisglycinate group showed a significantly greater reduction in ISI scores compared to the placebo group from baseline to Week 4 (-3.9 [95% CI: -5.8 to -2.0] vs -2.3 [95% CI: -4.1 to -0.4], respectively; p = 0.049). The effect size was small (Cohen's d = 0.2), indicating a modest benefit. Exploratory analyses suggested notably greater improvements among participants reporting lower baseline dietary magnesium intake, potentially indicating a subgroup of high responders. No significant differences were observed in other psychological outcomes.
Magnesium bisglycinate supplementation modestly improved insomnia severity in adults reporting poor sleep quality. Future research should include objective sleep assessments, longer intervention periods, and better characterization of potential high responders by systematically assessing baseline dietary magnesium intake and status.
Effect of magnesium bisglycinate supplementation on sleep and fatigue parameters in healthy adults reporting poor sleep quality; https://drks.de/search/en/trial/DRKS00031494 DRKS-ID: DRKS00031494.
评估补充甘氨酸镁对睡眠质量差的健康成年人失眠症状的影响。
这项随机、双盲、安慰剂对照试验纳入了155名年龄在18 - 65岁、自我报告睡眠质量差的成年人。参与者被随机分配至补充甘氨酸镁组（每日补充250毫克元素镁）或安慰剂胶囊组。在基线及整个研究的多个时间点，使用失眠严重程度指数（ISI）和其他心理问卷评估睡眠质量。应用针对基线ISI评分、年龄、性别、体重指数和职业进行调整的广义线性混合模型（GLMM）。
从基线到第4周，甘氨酸镁组的ISI评分较安慰剂组显著降低（分别为-3.9 [95%置信区间：-5.8至-2.0] 与 -2.3 [95%置信区间：-4.1至-0.4]；p = 0.049）。效应量较小（科恩d值 = 0.2），表明获益适度。探索性分析表明，报告基线饮食镁摄入量较低的参与者改善更为显著，这可能表明存在一个高反应亚组。在其他心理结果方面未观察到显著差异。
补充甘氨酸镁适度改善了睡眠质量差的成年人的失眠严重程度。未来的研究应包括客观睡眠评估、更长的干预期，并通过系统评估基线饮食镁摄入量和状态更好地刻画潜在高反应者的特征。
补充甘氨酸镁对睡眠质量差的健康成年人睡眠和疲劳参数的影响；https://drks.de/search/en/trial/DRKS00031494 试验注册号：DRKS00031494
